Unum Therapeutics (NASDAQ:UMRX) is scheduled to post its quarterly earnings results after the market closes on Monday, November 12th. Analysts expect Unum Therapeutics to post earnings of ($0.35) per share for the quarter.
Unum Therapeutics (NASDAQ:UMRX) last issued its earnings results on Monday, August 13th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.02. The firm had revenue of $1.67 million during the quarter, compared to analysts’ expectations of $2.45 million. On average, analysts expect Unum Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Shares of Unum Therapeutics stock opened at $7.19 on Friday. Unum Therapeutics has a 52-week low of $7.00 and a 52-week high of $17.66.
An institutional investor recently bought a new position in Unum Therapeutics stock. Bank of New York Mellon Corp purchased a new position in Unum Therapeutics Inc (NASDAQ:UMRX) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 12,304 shares of the company’s stock, valued at approximately $177,000. Hedge funds and other institutional investors own 51.50% of the company’s stock.
Several research analysts have issued reports on the stock. Zacks Investment Research cut shares of Unum Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, October 17th. Cowen reaffirmed a “hold” rating on shares of Unum Therapeutics in a report on Monday, September 17th. Wedbush lifted their target price on shares of Unum Therapeutics from $18.00 to $20.00 and gave the stock an “outperform” rating in a report on Tuesday, August 14th. Finally, Morgan Stanley lifted their target price on shares of Unum Therapeutics from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Thursday, October 11th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $20.67.
TRADEMARK VIOLATION NOTICE: This piece of content was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this piece of content can be accessed at https://sportsperspectives.com/2018/11/10/unum-therapeutics-umrx-to-release-earnings-on-monday.html.
Unum Therapeutics Company Profile
Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. Its lead product candidate is the ACTR087 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory non-Hodgkin lymphoma.
Featured Article: Should You Consider an Index Fund?
Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.